AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cance...(derive varying degrees ofbenefit from ch...),Health

Date:5/13/2008

derive varying degrees of benefit from chemotherapy, while patients with less aggressive, low grade (Grade 1) tumors usually derive no benefit. However, approximately 50 percent of all early stage breast cancer patients are diagnosed with an intermediate tumor grade (Grade 2). For these patients the appropriate choice of therapy is unclear. The clinical data published this month demonstrate that Aviara MGI accurately identifies Grade 1 and 3 tumors, and successfully re-classifies intermediate tumor grade (Grade 2) into cases with Grade 1-like or Grade 3-like outcomes.

"The importance of accurate tumor grading cannot be understated," said Dennis C. Sgroi, director of breast pathology at Massachusetts General Hospital and associate professor of pathology at Harvard Medical School, a senior author of the article. "A molecular tool such as MGI that can help separate intermediate-grade tumors into two distinct prognostic groups will go a long way in stratifying risk and improving treatment selection for breast cancer patients."

Researchers combined Aviara MGI and Aviara H/I in order to assess the overall impact of both molecular tumor grade and endocrine therapy benefit on patient outcome. H/I is a well-established biomarker that has been shown to predict both recurrence risk and endocrine benefit in more than 2,000 patients in numerous clinical studies. It assesses the likelihood of a patient to benefit from endocrine therapy by measuring the functionality of the estrogen signaling pathway inside the tumor cell itself. As such, H/I goes beyond conventional estrogen and progesterone receptor (ER/PR) testing. While patients who are ER/PR positive are assumed to benefit from endocrine therapy, the therapy fails in approximately 25 percent of those patients.

"Other gene-signature assays developed for breast cancer provide an improvement over tumor grade as a measure of breast cancer aggressiveness and likely benefit from chemotherapy. These different pr
'/>"/>

SOURCE AviaraDx, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
2. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
3. FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
6. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
7. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
8. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
9. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
10. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
11. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)